Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183196 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone
A Phase 3 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT00183196 is a Phase 3 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 150 participants.
The verdict
NCT00183196, a Phase 3 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether, after a period of abstinence, adding 6 weeks of gabapentin (a medication approved to treat seizures) to a standard 16-week naltrexone (an opiate blocking agent approved for the treatment of alcohol dependence) treatment protocol is helpful in decreasing relapse to drinking compared to naltrexone alone or placebo. All participants will receive alcohol counseling.
Interventions
- OTHER Inactive Placebo
- DRUG Naltrexone
- DRUG Naltrexone plus Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183196
The ClinicalTrials.gov registry entry for NCT00183196 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Inactive Placebo is the first listed.
NCT00183196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00183196 about?
NCT00183196 is a clinical study titled "Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone". The purpose of this study is to determine whether, after a period of abstinence, adding 6 weeks of gabapentin (a medication approved to treat seizures) to a standard 16-week naltrexone (an opiate blocking agent approved for the treatment of alcohol dependence) treatment protocol is helpful in decrea...
What is the current status of trial NCT00183196?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2003-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00183196?
The interventions under investigation include: Inactive Placebo (OTHER), Naltrexone (DRUG), Naltrexone plus Gabapentin (DRUG).
Who is sponsoring clinical trial NCT00183196?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.